All In Biotech

Drug Trial Radar · NCT05257265

A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Efficacy and Safety of Once Daily Centanafadine Capsules for the Treatment of Adolescents With Attention-deficit/Hyperactivity Disorder

Last checked: Nov 20, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 459 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

459

Actual

Start

Feb 2, 2022

Primary completion

Sep 29, 2023

Study completion Oct 5, 2023

Sponsor

Sponsor type
Industry
First posted
Feb 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 13 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial was conducted to evaluate the efficacy and safety of the Centanafadine once daily (QD) extended release (XR) capsules in adolescent participants (13 - 17 years, inclusive) with attention-deficit/hyperactivity disorder (ADHD).

Conditions

  • Attention-Deficit/Hyperactivity Disorder

Interventions

  • Centanafadine HydrochlorideDrug

    Capsule

  • PlaceboOther

    Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Attention-Deficit/Hyperactivity Disorder Rating Scale Version 5 (ADHD-RS-5)Time frame: From baseline to week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • For additional information regarding sites, contact 844-687-8522

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.